Berenberg upgrades Evonik stock to Hold with EUR 20.00 target

Published on 10/06/2026 at 11:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted EBITDA rose 24.00 percent to EUR 630.00 million in the second quarter of 2026. Evonik stock costs EUR 20.81 on October 6, 2026 after EUR 20.78.

Draufsicht auf Aktienzertifikat, ISIN-Karte DE000EVNK013 und Spezialchemie-Laborutensilien auf Marmor — Evonik Industries DE000EVNK013 als Flatlay mit Aktienzertifikat, ISIN-Karte und Chemielabor-Utensilien auf Marmor, Illustration mit AI erstellt.

Evonik stock was trading at EUR 20.81 at Lang & Schwarz on October 6, 2026 at 11:37 a.m. CEST, up EUR 0.03 or 0.14 percent versus the prior close of EUR 20.78. According to Investing.com, Berenberg upgraded Evonik from Sell to Hold and raised its price target from EUR 15.50 to EUR 20.00 in a study dated October 2, 2026.

Berenberg sees a EUR 20.00 target

The upgrade gives Evonik a more balanced analyst stance after Berenberg had argued that commoditization pressure in methionine and other businesses could force further earnings downgrades. The new EUR 20.00 target is EUR 0.81 below the Lang & Schwarz price, while the old EUR 15.50 target was EUR 5.31 below it.

Berenberg linked the change to takeover interest from BASF, which the analyst said could provide a floor for Evonik shares if discussions continue. The same report also identified falling methionine prices as a counter-factor, making the earnings outlook dependent on whether recent pricing support persists.

Second-quarter earnings support the case

Evonik's adjusted EBITDA rose 24.00 percent year over year to EUR 630.00 million in the second quarter of 2026, according to the Yahoo Finance transcript. The increase was attributed to higher volumes and prices, with each contributing 7.00 percent.

Evonik also raised its full-year 2026 EBITDA guidance to EUR 2.00 billion-2.20 billion from EUR 1.70 billion-2.00 billion, ICIS reported on September 22, 2026. The midpoint therefore increased from EUR 1.85 billion to EUR 2.10 billion, a EUR 250.00 million rise.

Stock stays near its yearly high

At EUR 20.81, Evonik stock stood 0.05 percent below its 52-week high of EUR 20.82 on October 6, 2026. The structured market data also put market capitalization at EUR 9.7 billion on that date, while the 52-week low was EUR 12.49.

Evonik's next scheduled reporting date is November 3, 2026, when it will report third-quarter 2026 business development, according to the company's investor relations calendar. That date will test whether the second-quarter earnings improvement and the higher outlook are holding into the next reporting period.

Price remains above the new target

At Lang & Schwarz, Evonik was trading at EUR 20.81 on October 6, 2026 at 11:37 a.m. CEST, plus 0.14 percent versus the prior close of EUR 20.78 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Evonik stock.